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Abstract
Background: The reliable diagnosis rate of diagnostic tests is provided by their
intervals with acceptable accuracy (e.g. Z90%) where a liver biopsy can be
avoided. Aims: To evaluate the overall accuracy and improve the reliable diagnosis
rates of blood tests for signiﬁcant liver ﬁbrosis. Methods: Five blood tests were
compared with Metavir ﬁbrosis (F) staging in 1056 patients with chronic hepatitis
C. Results: Area under the receiver operating characteristics (F0-1 vs. F2-4) were:
FibroMeter: 0.853, Fibrotest: 0.811, Fib-4: 0.799, aspartate aminotransferase to
platelet ratio index (APRI): 0.786 and Hepascore: 0.784 (Po10
 3 between tests).
The reliable diagnosis rates based on two traditional intervals deﬁned by thresh-
olds Z90% of negative predictive values (NPV) and positive predictive values
(PPV), diagnosing F0/1 and F2/3/4, respectively, were: FibroMeter: 43.5%, APRI:
19.6%, Fibrotest: 17.1%, Hepascore: 3.9%, Fib-4: 1.7% (Po10
 3). By dividing the
indeterminate interval by the diagnostic cut-off, two new intervals could be
diagnosed reliably: F1/2 and F1/2/3. Accordingly, the reliable diagnosis rate was
increased, e.g. FibroMeter: 75.5% (accuracy: 89.5%) with three intervals (F0/1, F1/
2, F2/3/4). It was possible to further increase this rate by using the more exportable
90% sensitivity/speciﬁcity thresholds, e.g. FibroMeter: 90.2% (accuracy: 86.4%).
By using the four intervals, the reliable diagnosis rate was 100% (accuracy: 89.5%
with predictive value (PV) and 87.5% with sensitivity/speciﬁcity). Conclusion:Re-
liable diagnosis is a diagnostic index devoted to clinical practice. Its rate can be
increased by creating new intervals between diagnostic cut-off and 90% PVs or
sensitivity/speciﬁcity thresholds. This increased the overall accuracy from 78.1 to
89.5% and reduced the need for a liver biopsy from 56.5 to 0% with the most
accurate test.
Score-based blood tests for liver ﬁbrosis that take into
account several blood or clinical markers have been
available for about 10 years (1). They are usually
designed to diagnose signiﬁcant ﬁbrosis, which
includes all stages with bridging ﬁbrosis (2).
Signiﬁcant ﬁbrosis has been adopted as a target
because it can be identiﬁed using semiquantitative
histological staging in a patient with chronic hepatitis
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The overall accuracy of several blood tests is
considered to be excellent. However, this accuracy is
variable as a function of blood test value with
maximum accuracy at the extreme values and
minimum accuracy in the median values (see Fig. 1).
A reliable diagnosis corresponds to the intervals of
blood test values where the diagnostic accuracy is
considered to be sufﬁciently reliable for clinical prac-
tice. Thus, in these patients, a liver biopsy is consid-
ered to be avoidable. Previously, the intervals of
reliable diagnosis were deﬁned by the thresholds
provided by 90% predictive values (PV) (3, 4). How-
ever, how these intervals are determined has never
been examined or commented on in detail and
thorough statistical consideration might cast some
doubts on the previous statements.
Thus, the main aim of this study was to describe
comprehensively the performance of original blood tests
in identifying intervals of reliable diagnosis, and to
e x a m i n ew h e t h e ri tw a sp o s s i b l et oi m p r o v er e l i a b l e
diagnosis rates for signiﬁcant ﬁbrosis. The secondary aims
were to compare the overall accuracy and reliable diag-
nosis rates between several blood tests and evaluate other
diagnostic targets. To achieve these objectives, we per-
formed a meta-analysis with individual data using a large
population of patients for whom liver biopsy and numer-
ous blood markers were available for evaluation and
comparison. We decided to compare two simple tests
(based on ratio), aspartate aminotransferase to platelet
ratio index (APRI) (5) and Fib-4 (6), including indirect
ﬁbrosis markers, and three sophisticated tests, based on
algorithms provided by logistic regression: Fibrotest in-
cluding indirect markers (3) and two mixed tests, includ-
ing indirect and direct markers: Hepascore (7) and
FibroMeter (8).
Methods
Data source
Using the Medline database and a manual search, we
systematically reviewed the literature from 1997 to
June 2007 for studies comparing FibroMeter and
Fibrotest in patients with chronic viral hepatitis C for
whom liver biopsy data were available. Information
provided by the tests enabled Hepascore, APRI and
Fib-4 to be calculated. Three independent publications
were retrieved. The ﬁrst study, involving one centre,
Angers, was the original publication that described the
FibroMeter test (8). The second study included two
independent centres, Provence/Co ˆte d’Azur (PACA)
and Tours (9), and the third was from Grenoble (4).
The PACA centre incorporated three secondary and
two tertiary care settings. Two additional, currently
unpublished populations were provided by Angers
and Bordeaux (10). Thus, individual patient data were
available from ﬁve centres, independent for study
design, patient recruitment, blood marker determina-
tion and interpretation of liver histology.
Patients
The inclusion and exclusion criteria were very similar
at all ﬁve centres. Patients with chronic viral hepatitis
C were prospectively included from 1994 to 2007 if
they had anti-hepatitis C virus (HCV) antibodies,
HCV RNA in serum and available liver biopsy and
blood markers. Fasting blood samples were collected
immediately before or no more than 3 months after
the liver biopsy was performed. Patients in the Tours
and PACA centres were excluded if their liver speci-
mens were smaller than 15mm. Other exclusion
criteria were additional causes of liver disease,
0.5
0.6
0.7
0.8
0.9
1
0
Blood test value
A
c
c
u
r
a
t
e
l
y
 
c
l
a
s
s
i
f
i
e
d
 
r
a
t
e
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
Fig. 1. Diagnostic accuracy as a function of the value of ﬁve blood tests (split into 2.5% percentiles). Curves were smoothed by
polynomial regression.
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complicated cirrhosis, anti-ﬁbrotic treatment in the
previous 6 months and alcohol consumption of more
than 30g/day in the 5 years before inclusion. Overall,
the ﬁve centres provided 1535 patients; 479 were not
included because of missing criteria or data, leaving a
core population of 1056 patients. The study protocol
conformed to the ethical guidelines of the current
Declaration of Helsinki and was approved by local
ethics committees.
Blood measurements
Blood samples were processed independently at each
centre. The variables determined were platelet count,
urea, bilirubin, g-glutamyl transpeptidase, aspartate
aminotransferase (AST) and alanine aminotransferase,
prothrombin index, apolipoprotein A1, haptoglobin,
hyaluronic acid (Corgenix) and a-2-macroglobulin
(Dade Behring). Direct markers were measured in
either fresh blood or frozen samples of serum stored
at   201C. Indirect markers were usually measured
in fresh blood. Automats and assay techniques varied
between the centres (details not provided), with the
exception of apolipoprotein, a-2-macroglobulin and
hyaluronic acid. Blood tests were calculated
according to published formulas (5–8, 10). The Fibro-
Meter score was slightly improved by taking patient
sex into account as described in a previous study (11).
AST used in APRI was divided by a common upper
limit of normal, as several studies performed in
numerous laboratories have shown excellent inter-
laboratory reproducibility (12).
Liver biopsy
Liver biopsies were performed using Menghini’s tech-
nique with a 1.4–1.6-mm-diameter needle. Biopsy
specimens were ﬁxed in a formalin–alcohol–acetic
solution and embedded in parafﬁn; 5-mm-thick sec-
tions were then cut and stained with haematoxylin–
eosin–saffron. Liver ﬁbrosis was staged from F0 to F4
according to the Metavir staging system (13). Three
diagnostic targets were deﬁned as follows: signiﬁcant
ﬁbrosis (main target), F21F31F4; severe ﬁbrosis,
F31F4; and cirrhosis, F4. Readings were performed
by independent blinded senior pathologists specialized
in hepatology. Histological assessments were per-
formed twice by the same pathologist in Grenoble,
once in Bordeaux and oncebyeach of twopathologists
in Angers, Tours and PACA, with a common ﬁnal
reading in cases of disagreement. Biopsy specimens
were not re-examined centrally, as we have shown in a
previous study (involving most of the same patholo-
gists) that inter-observer agreement on the Metavir
staging system is excellent among senior hepato-
pathologists (14).
Methodology
End points
The main objective of this study was to evaluate the
rates of overall accuracy and reliable diagnosis of
blood tests for signiﬁcant ﬁbrosis and other ways to
increase the rate of reliable diagnosis. Secondary
objectives were to evaluate the overall accuracy for
other diagnostic targets, to compare the performance
of blood tests and to evaluate the robustness of PVs.
Deﬁnitions
Diagnostic target
The main objective of a blood test, usually deﬁned by
two ranges of all stages of ﬁbrosis, with a diagnostic
cut-off between them, e.g. signiﬁcant ﬁbrosis (yes/no).
Overall accuracy (or diagnostic accuracy or correct
diagnosis)
Sum of true positives and negatives as a proportion of
the whole population.
Reliable diagnosis
Corresponds to the intervals of blood test values where
the diagnostic accuracy is considered to be sufﬁciently
reliable for clinical practice. Considering the diagnos-
tic target of blood test in clinical practice, this means
that a liver biopsy can be avoided. Thus, with the
traditional deﬁnition based on 90% PVs, a reliable
diagnosis for a patient means Z90% chance to be F0/1
in the lower interval and Z90% chance to be ZF2 in
the highest interval of blood test values. The indeter-
minate interval is the zone outside of these reliable
intervals.
Diagnostic cut-off
The diagnostic cut-off of a blood test value, usually
provided by binary logistic regression, distinguishes
patients with or without the diagnostic target. Here, it
was ﬁxed in two ways: a priori to 0.5 according to
statistical convention (with the exception of APRI and
Fib-4, which are simple ratios), and a posteriori
according to the highest Youden index (Se1Spe 1)
or the maximum overall accuracy to optimize test
performance. The ﬁxed a priori cut-off does not always
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is applied in populations larger than the original one.
Classiﬁcation/misclassiﬁcation rate
This method was called ‘performance proﬁle’ in a
recent article (9). Brieﬂy, the misclassiﬁcation rate of
a blood test for signiﬁcant ﬁbrosis was calculated using
Metavir staging as a reference. Thus, a patient with
Metavir F0 or F1 classiﬁed in the signiﬁcant ﬁbrosis
group by blood test was considered as misclassiﬁed
and vice versa. The misclassiﬁcation rate was calcu-
lated in each, or in possibly combined Metavir ﬁbrosis
(F) stage(s) as determined by histological staging.
Finally, misclassiﬁcation rates were compared between
pairs of blood tests using the McNemar test. Here, to
simplify the presentation, the results are mainly ex-
pressed as the inverse proportion of correctly classiﬁed
patients.
Statistical analysis
The diagnostic accuracy of each test was expressed as
the area under the receiver operating characteristic
(AUROC), the overall accuracy and detailed indices
such as likelihood ratio and diagnostic odds ratio
(15–17). AUROCs were compared using the non-
parametric Delong test (18). Data were reported
according to STARD statements (19) and thus ana-
lysed on an intention-to-diagnose basis. Importantly,
therewas no exclusionowingto false bloodtestresults.
The size of the population was that necessary to detect
a signiﬁcant difference between the two most accurate
tests according to a preliminary study (11) in the
diagnosis of cirrhosis, which was the diagnostic target
with the least difference between blood tests. With an
a-risk of 0.05, a b-risk of 0.2, cirrhosis prevalence of
0.11, AUROC correlation of 0.75 and bilateral testing,
the required sample size was 910 patients for the
following AUROC values: FibroMeter: 0.93, Fibrotest:
0.89, as provided by the previous study (11).
Results
Patient characteristics
The principal characteristics of the 1056 patients were
as follows: sex: 59.5% male; mean age: 45.6 12.5
years; Metavir F stage: F0: 4.4%, F1: 43.5%, F2: 27.0%,
F3: 14.0%, F4: 11.2%; and mean liver specimen length:
21 8mm. Thus, the prevalence of the main diagnos-
tic target, signiﬁcant ﬁbrosis, was 52%. There was no
correlation between Metavir F stage and liver speci-
men length (rs: 0.00, P=0.872), thus reﬂecting the
pathologist expertise (14); 84.0% of liver specimens
were Z15mm and 58.2% were Z20mm.
Overall performance
The main indices of the diagnostic accuracy for
signiﬁcant ﬁbrosis of the tests are presented in Table
1. AUROC for different diagnostic targets are pre-
sented in Table 2. Brieﬂy, AUROC values for cirrhosis
were higher than those for severe ﬁbrosis, which in
turn were higher than those for signiﬁcant ﬁbrosis as
the diagnostic target. The AUROC of FibroMeter was
signiﬁcantly higher than that of other blood tests for
signiﬁcant ﬁbrosis, severe ﬁbrosis and cirrhosis (with
the exception of Hepascore in cirrhosis). Globally,
AUROCs of other blood tests were not signiﬁcantly
different (exceptions: Fibrotest superior to Hepascore
for signiﬁcant ﬁbrosis, Fib-4 superior to APRI for
severe ﬁbrosis and cirrhosis and Hepascore superior
to APRI for cirrhosis). The plots of the diagnostic
accuracy as a function of blood test values are depicted
in Figure 1. They clearly show that accuracy was
maximum at the extremes and minimum in the
middle of blood test values.
Table 1. Diagnostic indices of blood tests for signiﬁcant ﬁbrosis
Test Cut-off kw Se Spe 1PV  PV 1LR  LR DOR OA AUROCz
FibroMeter 0.419 0.560 80.0 76.0 78.5 77.6 3.33 0.26 12.65 78.1 0.853
Fibrotest 0.435 0.493 67.7 81.9 80.1 70.2 3.74 0.39 9.48 74.5 0.811
Hepascore 0.465 0.450 66.2 79.1 77.5 68.3 3.17 0.43 7.42 72.4 0.784
APRI 0.548 0.454 62.4 83.5 80.5 67.0 3.78 0.45 8.38 72.5 0.786
Fib-4 1.116 0.458 73.9 71.9 74.2 71.6 2.63 0.36 7.25 73.0 0.799
Diagnostic cut-off determined a posteriori according to maximum Youden index; the maximum overall accuracy cut-off (not shown) was close owing
to prevalence (0.52) of diagnostic target.
wk index measuring the agreement between a blood test and a liver biopsy for the diagnosis of signiﬁcant ﬁbrosis.
zAUROC is independent of cut-off.
AUROC, area under the receiver operating characteristic; DOR, diagnostic odds ratio; LR, likelihood ratio; OA, overall accuracy; PV, predictive value; Se,
sensitivity; Spe, speciﬁcity.
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The misclassiﬁcation rates of blood tests for sig-
niﬁcant ﬁbrosis based on liver biopsy as a function
of Metavir F stage are presented in Figure 2. The
comparisons of correct classiﬁcation rates are detailed
in the Supplementary Material (Table S1). Brieﬂy, the
overall rate of correct classiﬁcation was signiﬁcantly
higher with FibroMeter compared with all other blood
tests, which in turn did not show signiﬁcant differ-
ences between them. The correct classiﬁcation rate of
signiﬁcant ﬁbrosis by FibroMeter was signiﬁcantly
higher than that of other blood tests in all single
or combined stages of signiﬁcant ﬁbrosis. Conversely,
the correct classiﬁcation rate for non-signiﬁcant
ﬁbrosis (  F1) was signiﬁcantly inferior with
FibroMeter compared with Fibrotest and APRI.
Reliable diagnosis
Predictive values
Predictive values can be easily inferred and compared
from Figure 1. We ﬁrst looked at traditional 90%
positive predictive values (PPV) and negative (NPV)
predictive values. The corresponding thresholds and
patient rates are depicted in Figure 3 and detailed in
the Supplementary Material (Table S2). Brieﬂy, the
Table 2. AUROC (95% CI) of blood tests (grey cells) and their comparisons (P-value of the Delong test) as a function of the diagnostic
target
Signiﬁcant ﬁbrosis Severe ﬁbrosis Cirrhosis
FibroMeter 0.853 (0.830–0.876) 0.885 (0.863–0.906) 0.907 (0.885–0.929)
Fibrotest 0.811 (0.785–0.838) 0.837 (0.809–0.865) 0.882 (0.855–0.910)
Hepascore 0.784 (0.757–0.812) 0.834 (0.806–0.862) 0.896 (0.868–0.924)
APRI 0.786 (0.759–0.814) 0.822 (0.792–0.852) 0.841 (0.803–0.880)
Fib-4 0.799 (0.772–0.825) 0.843 (0.816–0.871) 0.869 (0.835–0.903)
All blood tests o10
 3 o10
 3 o10
 3
FibroMeter vs. Fibrotest o10
 3 o10
 3 0.041
FibroMeter vs. Hepascore o10
 3 o10
 3 0.203
FibroMeter vs. APRI o10
 3 o10
 3 o10
 3
FibroMeter vs. Fib-4 o10
 3 o10
 3 0.008
Fibrotest vs. Hepascore 0.004 0.307 0.592
Fibrotest vs. APRI 0.059 0.324 0.131
Fibrotest vs. Fib-4 0.232 0.863 0.605
Hepascore vs. APRI 0.860 0.479 0.013
Hepascore vs. Fib-4 0.327 0.587 0.202
APRI vs. Fib-4 0.210 0.037 0.021
Signiﬁcant differences are in bold characters.
APRI, aspartate aminotransferase to platelet ratio index; AUROC, area under the receiver operating characteristic.
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signiﬁcant ﬁbrosis by a blood test was in the following
signiﬁcantly decreasing order: FibroMeter: 43.5%,
APRI: 19.6%, Fibrotest: 17.1%, Hepascore: 3.9% and
Fib-4: 1.7% (Po10
 3 between tests).
Figure 4 shows the proportion of Metavir F stages as a
function of reliable diagnosis intervals deﬁned by the
Z90% PV for the most accurate test (FibroMeter). There
was very little misclassiﬁcation of extreme ﬁbrosis stages
in these two intervals; thus, there was no F0 in the
FibroMeter interval with Z90% PPV, whereas there was
0.5% of F3 and 0% of F4 in the FibroMeter interval with
Z90% NPV. In the indeterminate interval, 79.7% of
patients were F1 or F2 and 17.8% of patients were F3 or
F4 (Fig. 4a). However, when this indeterminate interval
was divided into two new intervals according to the a
priori diagnostic cut-off of 0.5 (Fig. 4b), in the interval
between 90% NPVand o0.5 the proportion of F1 or F2
was 88.9% with 6.8% of severe ﬁbrosis (F314) or 0.6%
F4. The proportions in the interval between 0.5 and 90%
PPV were: severe ﬁbrosis (F314): 32.3%, F4: 10.5%, F1
or F2: 67.7% and F1/2/3: 89.5%. Thus, one can easily
increase the reliable diagnosis rate by considering patients
within the interval between Z90% NPV threshold and
o0.5 as F1 or F2. Consequently, we obtained three
intervals with reliable diagnoses: F0 or F1 in the Z90%
NPV interval, F1 or F2 within the interval between 90%
NPV threshold and o0.5 cut-off and ZF2 in the
Z90% PPV interval (with a majority of F3 or F4:
69.2%). These three intervals with approximately 90%
accuracy included 75.5% of the population, among
whom 89.5% of the patients were correctly classiﬁed. It
w a sp o s s i b l et od e t e r m i n et h es a m et h r e er e l i a b l ei n t e r v a l s
with other blood tests (thresholds in Table S2). Finally, by
including the new third interval (between 0.5 and 90%
PPV), it was possible to obtain the following four
intervals with the respective reliable diagnoses: F0/1, F1/
2, F1/2/3 and F2/3/4 in 100% of the population, among
whom 89.5% were correctly classiﬁed with FibroMeter.
We also looked at the robustness of PV thresholds.
Indeed, PVs are usually deﬁned by a threshold with a
corresponding precise value, e.g. 90% NPV, but in fact
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Fig. 4. Proportions of Metavir ﬁbrosis stage (F) according to
thresholds of Z90% negative (NPV) and positive predictive
values (PPV) with a single indeterminate interval for signiﬁcant
ﬁbrosis with FibroMeter (a). (b) The previous indeterminate
interval was divided according to diagnostic cut-off at 0.5,
providing two new intervals between this cut-off and the
thresholds of predictive values: second interval between 90%
NPV threshold and diagnostic cut-off; third interval between
diagnostic cut-off and 90% PPV threshold.
Table 3. Patient rates (% of the whole population) with reliable
diagnoses deﬁned by different thresholds of diagnostic indices
for signiﬁcant ﬁbrosis by Fibrotest and FibroMeter
Indices
Threshold
Patient rates with
reliable diagnosis (%)
(%)
Fibro-
Meter
Fibro-
test P
Positive and negative
predictive values
95 21.1 10.8 o10
 4
90 43.5 17.1 o10
 4
Sensitivity and
speciﬁcity
95 47.5 36.1 o10
 4
90 69.5 57.9 o10
 4
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with Z90% NPV. The curves of NPVand PPV for the
ﬁve blood tests are detailed in the appendix (Fig. S1).
Brieﬂy, NPV curves showed the following pattern of
decreasing robustness for threshold, i.e. progressive
decrease: FibroMeter, Fibrotest, Hepascore, Fib-4 and
APRI, the latter three having non-robust (irregular)
shapes for high values. The shapes of PPV remained
roughly the same order but were more robust for
thresholds.
Other indices
In Table 3, we have determined other intervals of
reliable diagnosis for the two most accurate tests by
using other thresholds for PVs and sensitivity (Se) and
speciﬁcity (Spe). Figure 5 shows that thresholds of
90% Se/Spe provided a higher patient rate with two
intervals of reliable diagnosis (e.g. 69.5% for Fibro-
Meter, gain: 26.0%) or correct classiﬁcation at the
expense of a minor loss in ensuing PVs (e.g. 4.3% for
FibroMeter, Fig. 5) compared with the two intervals of
reliable diagnosis deﬁned by 90% PVs. Figure 6 shows
the proportion of Metavir F stages as a function of
reliable diagnosis intervals deﬁned by Z90% Se/Spe
for the most accurate test (FibroMeter). There was
no false extreme stage (F0 or F4) with 90% Se/Spe
intervals in FibroMeter. When we divided the indeter-
minate interval according to the diagnostic cut-off, we
observed in the new lower interval: severe ﬁbrosis in
8.6% (F4: 1.0%) and F1 or F2 in 89.0%; and in the new
upper interval: severe ﬁbrosis in 19.2% (F4: 3.0%), F1
or F2 in 80.8% and F1/2/3 in 97%. The three intervals
with reliable diagnosis (  F1, F1/2, ZF2) included
90.2% of the population, among whom 86.4% were
correctly classiﬁed. Finally, by including the new third
interval (between 0.5 and 90% Spe), it was possible to
0
10
20
30
40
50
60
70
80
90
100
95%
predictive
values
 90%
predictive
values
95% Se
Spe 
90% Se
Spe 
Reliable diagnosis
Fibrotest
Reliable diagnosis
FibroMeter
Correctly classified
Fibrotest
Correctly classified
FibroMeter
Predictive values
Fibrotest
Predictive values
FibroMeter
Fig. 5. Rate (% of the whole population) on y-axis of patients with reliable diagnoses (squares), correctly classiﬁed patients (triangles)
and resulting observed predictive values (PV) (circles) according to two intervals of reliable diagnosis deﬁned by different
predetermined thresholds (90 and 95%) of diagnostic indices (PVs, sensitivity (Se), speciﬁcity (Spe)) on x-axis for signiﬁcant ﬁbrosis
by Fibrotest (blue) and FibroMeter (red).
90% Spe
FibroMeter >=0.5
FibroMeter <0.5
90% Se
M
e
t
a
v
i
r
 
f
i
b
r
o
s
i
s
 
s
t
a
g
e
 
(
%
)
100
90
80
70
60
50
40
30
20
10
0
F
4
3
2
1
0
Fig. 6. Proportions of Metavir ﬁbrosis stage (F) according to
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nosis: F0/1, F1/2, F1/2/3, and F2/3/4 in 100% of the
population, among whom 87.5% were correctly classi-
ﬁed. Comparisons between reliable diagnoses pro-
vided by 90% PV or Se/Spe thresholds are presented
in Table 4.
Sensitivity analysis
In order to test the inﬂuence of sensitive variables,
performance was calculated in the whole population,
then without the original population of the Fibro-
Meter (8) and in liver specimen length Z15mm. Re-
spective AUROCs were as follows: FibroMeter: 0.853,
0.847, 0.852; Fibrotest: 0.811, 0.810, 0.804; Hepascore:
0.784, 0.776, 0.775; APRI: 0.786, 0.790, 0.792; and Fib-
4: 0.799, 0.798, 0.803 (Po10
 3 between tests for each
of the three comparisons). There was thus no change
in the order of signiﬁcance.
Discussion
Diagnostic accuracy
As Table 2 shows, the order of performance of blood
tests for signiﬁcant ﬁbrosis was: FibroMeter4
Fibrotest   Hepascore   APRI   Fib-4. The present
study validates the performance of the recently de-
scribed simple test Fib-4 (6). However, this test was
originally reported for the diagnosis of severe ﬁbrosis
where it was more accurate than APRI, the other
simple test. In contrast, its accuracy was not signiﬁ-
cantly different from that of other tests for the usual
diagnostic target of signiﬁcant ﬁbrosis, except for the
FibroMeter. These differences in diagnostic character-
istics are well explained by the performance proﬁle.
Indeed, FibroMeter had an appreciably higher accu-
racy rate than Fib-4 in all stages of signiﬁcant ﬁbrosis.
Fib-4 was in turn more accurate than other tests (Fig.
2). The only test with 100% accuracy for signiﬁcant
ﬁbrosis at the extreme ﬁbrosis stages (F0 and F4) was
FibroMeter.
Sensitivity analysis showed no particular effect of
the original population on FibroMeter (8). The centre
effect was examined in another study issued from the
same cohort: the coefﬁcient of variation of diagnostic
cut-off of Fibrometer was low, 4%, and this was
signiﬁcantly lower than that of other blood tests (20).
The long recruitment period and the proportion
of patients not included (31.2%) are limitations of
the study; therefore, an independent validation is
desirable.
Reliable diagnosis
Several cut-offs or thresholds can be distinguished
within a diagnostic score or a blood test.
Diagnostic cut-off
The diagnostic cut-off distinguishes patients with or
without the diagnostic target. Although diagnostic
cut-offs are rarely reported, they are important and
can be a source of discrepancy and/or controversy (21,
22). Because of this, determining and reporting the
best diagnostic cut-off should always be done, espe-
cially in pivotal papers.
Predictive values
The other thresholds are those concerning a reliable
diagnosis. A patient-based approach was adopted
previously in this area, with thresholds corresponding
to 90% PPVand NPV. In NPVand PPVranges, a liver
biopsy is considered to be unnecessary for ﬁbrosis
staging (3, 4). The plot of diagnostic accuracy as a
function of blood test values (Fig. 1) shows the reliable
diagnosis intervals determined by 90% PVs that varied
markedly among tests, from 43.5% for FibroMeter to
1.7% for Fib-4 (Fig. 3).
Table 4. Comparison of patient rates (%) with correct classiﬁcation by FibroMeter in reliably diagnosed patients or in the whole
population, as a function of 90% thresholds for predictive value or Se/Spe and the number of reliable intervals considered
Reliable intervals Reliable diagnosis (N) Whole population
N F0/1 F1/2 F1/2/3 F2/3/4
Patients (% whole population) Correctly classiﬁed (%) Correctly classiﬁed (%)
PV Se/Spe PV Se/Spe PV Se/Spe
2 x – – x 43.5 69.5 90.0 85.6 39.2 59.5
3 x x – x 75.5 90.2 89.5 86.4 67.6 78.0
4 x x x x 100 100 89.5 87.5 89.5 87.5
Indeterminate intervals are in grey cells.
PV, predictive value; Se, sensitivity; Spe, speciﬁcity.
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limits.
Firstly, they are based on liver specimen as a
reference, which has its own limits, i.e. sampling error
(23) and observer variability (14). The inter-observer
variability is high in intermediate ﬁbrosis stages,
especially Metavir F2 and F3 (14), and therefore could
be largely responsible for the apparent decrease of
performance of a blood test in intermediate ﬁbrosis
stages and corresponding blood test values. It could be
argued that the variability of the blood test may be
worse than the reference liver biopsy in intermediate
stages. However, several lines of argument support the
opposite. We have already observed that the variability
of a blood test could be weaker than its reference.
Thus, the dispersion of the area of ﬁbrosis in each
ﬁbrosis stage was less when it was expressed as a blood
test rather than the morphometric measurement from
which it was derived (8). The blood test score is
implemented in an original population with the less-
biased measurements (specimen length, expert on
consensus reading of liver biopsy). We have recently
shown that the reproducibility of blood tests was far
better than that of histological readings when blood
tests and liver specimens were determined in routine
conditions (24). Thus, the exportability of blood tests
is easier and better than that of liver biopsy interpreta-
tion; in other words, it can be easier to reproduce a
manufactured copy than the original hand-crafted
manuscript.
Secondly, the PVs depend on the prevalence of the
diagnostic target and are therefore not easily exporta-
ble. Thus, in the whole original population of Fibrotest
(3), the 90% PV thresholds (corresponding Fibrotest
values: 0.20 and 0.80) included 50% of the population
vs. 17.1% in our population (corresponding Fibrotest
values: 0.057 and 0.785). Then again, the previous
Fibrotest threshold values of the original population
(0.20 and 0.80) included 40.7% of patients in the
present population (Po10
 4 vs. 17.1%) with NPVat
81.0% and PPV at 91.8%. In the second group of the
original Fibrotest population, the 90% PV thresholds
corresponded to Fibrotest values of 0.10 and 0.60 (3).
Thus, the differences in the reliable diagnosis rates are
very signiﬁcant between these three populations. This
reﬂects the variability in PV, which is probably attri-
butable to the difference in the prevalence of F0: 4% in
the present population vs. 17% in the pivotal popula-
tion of Fibrotest (3). In this respect, it would be more
reliable to also report Se and Spe at a certain threshold
because they do not depend on the prevalence of the
diagnostic target. They can be used with conﬁdence in
studies on comparisons between populations. PVs can
also be reported because they provide information on
the diagnostic performance.
It should be kept in mind that Se/Spe reﬂects the
diagnostic performance in a population whereas PVs
reﬂect the diagnostic performance in a given patient.
Because of this, clinicians prefer PVs. However, PVs
are not adapted to blood tests because they are derived
from carefully selected patients (hospital recruitment,
liver biopsy performed) and thus difﬁcult to use in
patients close to the general population, i.e. in most
clinical settings where blood tests are applied.
Thirdly, the thresholds of PVs are not always robust.
Indeed, PVs, especially NPV, are very sensitive to the
threshold with a non-progressive change in the high
PVs, which is more marked in some tests. This has
already been noted for Fibrotest (3), and is responsible
for a variable PV for close blood test values and a
marked variability of comparison between blood tests
when the threshold varies, even slightly. All these
causes of weak statistical robustness preclude reliable
and extensive clinical application of PVs. It should be
noted that thresholds of Se and Spe are robust because
their plots as a function of blood test values are
progressive by construction.
There are several possibilities to increase the reliable
diagnosis intervals of blood tests.
Se/Spe
The ﬁrst is to consider the intervals provided by Se/Spe
indicesas suggested previously. The present study (Fig.
5) shows that by using two (traditional) or three
reliable intervals, it was possible to markedly increase
the rate of patients correctly classiﬁed or reliably
diagnosed with Se/Spe compared with PVs at the same
90% threshold level, at the expense of a weak loss of
PVor accuracy.
New intervals deﬁned by diagnostic cut-off
Secondly, as Figures 4 and 6 clearly show, in addition
to the two traditional intervals of reliable diagnosis,
one can delineate two additional intervals between the
PVs or Se/Spe thresholds and the diagnostic cut-off.
We thus obtain four successive intervals, allowing the
following reliable diagnoses: F0/1, F1/2, F1/2/3 and F2/
3/4. With FibroMeter, the rate of reliable diagnosis
increased from 43.5 to 100% and that of the correct
diagnosis from39.2to 89.5%(PVs)or 87.5%(Se/Spe).
It is noteworthy that these ﬁgures of correct diagnosis
correspond to the overall accuracy, which was thus
markedly improved compared with the overall accu-
racy of the blood test initially designed for signiﬁcant
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ﬁbrosis stages, which seems to be a broad diagnosis.
However, the majority of patients were F0/1 in the ﬁrst
interval (90% considering the PV threshold), F1/2 in
the two middle intervals (80%) and F3/4 in the last
interval (69%).
What choice in clinical practice?
The ﬁrst thing to consider is the number of reliable
intervals. By increasing this number from 2 to 4, the
rates of patients with reliable or correct diagnoses are
increased (Table 4). The inconvenience is a change in
the diagnostic target as the two middle intervals are
not within the scope of the initial diagnostic target.
However, the accuracy for ﬁbrosis staging is increased.
The second thing to consider is the type of thresholds.
Se/Spe thresholds provide a marked increase in the
rates of patients with reliable or correct diagnoses in
the whole population at the expense of a small loss in
accuracy among patients with reliable diagnoses com-
pared with PVs (note that this loss decreases from 4.4
to 2% when increasing the number of reliable inter-
vals, Table 4). However, this advantage is lost in the
case of four reliable intervals. Thus, we propose to
choose the option of four reliable intervals, deﬁned by
PV thresholds (and diagnostic cut-off), which pro-
vides the highest rate of correct diagnosis (89.5%) in
the whole population. Nevertheless, this proposal will
need validation in other populations. If we consider
only the diagnostic target of signiﬁcant ﬁbrosis, the
indeterminate intervals with unreliable diagnosis (F1/
2 and F1/2/3) might lead to a liver biopsy. However,
these indeterminate intervals are mainly hampered by
liver interpretation whereas several indirect arguments
suggest that blood tests can be used reliably, especially
when they are applied to the general population,
provided pre-analytical and analytical causes of varia-
bility are controlled (12). These indeterminate inter-
vals can also be circumvented by transforming blood
tests into semiquantitative variables with correspond-
ing Metavir F stages (20) or reduced by sequential
algorithms (25).
In conclusion, the present study shows that there is
no parallelism between the rates of overall accuracy
and reliable diagnosis of blood tests. These character-
istics were signiﬁcantly different among the evaluated
blood tests. A third and fourth interval between the
PVs or Se/Spe thresholds and diagnostic cut-off can
substantially expand the proportion of patients with
reliable diagnoses for ﬁbrosis staging compared with
the previously published method, and even more so
for overall accuracy (up to 89.5%). Finally, in clinical
practice, a reliable diagnosis can be made as a function
of blood test values divided into four intervals: F0/1,
F1/2, F1/2/3 and F2/3/4, with the extreme intervals
corresponding to the initial diagnostic target.
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Supplementary material
The following supplementary material for this article is
available online:
Table S1. Accurate classiﬁcation rate for signiﬁcant
ﬁbrosis (grey cells) by the different blood tests as a function
of ﬁbrosis stage according to Youden diagnostic cut-off (see
Table 1). Signiﬁcant differences are in bold characters. A rate
of 97.7% in F4 means that 97.7% of patients with cirrhosis
were correctly classiﬁed as having signiﬁcant ﬁbrosis.
Table S2. Patient rates with reliable diagnosis deﬁned
by thresholds of 90% negative (NPV) and positive (PPV)
predictive values for signiﬁcant ﬁbrosis according to the
blood tests. For example, the four reliable intervals for
FibroMeter were deﬁned according to the following thresh-
olds: 0 to 0.192, 40.192 to o0.5, Z0.5 to o0.853 and
Z0.853 to 1.
Fig. S1. Negative (top) and positive (bottom) PV
curves as a function of blood test value. APRI and Fib-4
were standardized by binary logistic regression.
This material is available as part of the online article
from: http://www.blackwell-synergy.com/doi/abs/10.1111/
j.1478-3231.2008.01789.x (this link will take you to the
article abstract).
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